Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Reveals Development Strategies In China

This article was originally published in PharmAsia News

Executive Summary

Shanghai Roche Pharmaceuticals CEO Zhou Ping-Shan has revealed the company's development plans in China in a recent interview. First is focus: Roche enjoys a leading position in such key therapeutic areas as oncology, virology and transplant by relying on its strong R&D and innovative capability. It is committed to promoting local pharmaceutical industry innovation and has set up an R&D center as well as a pharmaceutical development center. Second is the company's emphasis on collaboration with the Chinese biopharmaceutical industry. Roche has built up close partnerships with local universities, academic institutions and biopharmaceutical enterprises. Zhou notes that pharmaceutical enterprises must adapt rapidly to China's policy and reform as the nation's health care is in a revolutionary stage. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069070

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel